Your Article Summary
See Latest ArticlesTeva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
Active Biotech, 06/26/09
Teva Pharmaceutical Industries Ltd. and Active Biotech announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis. BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Primary endpoint reached in Active Biotechs TASQ Phase II clinical trial in prostate cancer patients
Active Biotech, 12/14/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia
Neuropsychopharmacology, 12/15/09
Treatment with Olanzapine is Associated with Modulation of the Default Mode Network in Patients with Schizophrenia
Neuropsychopharmacology, 12/15/09
An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas
Journal of Pharmacy and Pharmacology, 12/15/09